Gold and silver prices are slightly lower in early U.S. trading Monday, on routine downside corrections after recent gains.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
Michigan Approves Bill Expanding Access to Medical Cannabis Licenses
Michigan Gov. Gretchen Whitmer has signed legislation expanding the number of people eligible for medical cannabis licenses, including those previously barred due to a cannabis-related misdemeanor or felony.
Gold price extends gains in Pakistan
Gold rose on Monday boosted by concerns regarding uncertain economic conditions which have once again sparked a flight from risky commodities towards safer ones.
Gold, silver and platinum ready for blastoff
Gold, silver and platinum appear to be on the launching pad, ready to blast off to the upside.
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
Trevor Gerszt: Increasing Demand Could Boost the Silver Price
One of the issues facing the purchase of any sort of asset is the uncertainty of its price.
Gold prices can push through $1,800 as the Fed is in no hurry to raise interest rates
The gold market is once again in striking distance of $1,800.
Novamind Reports FY2021 Financial Results and Operating Highlights
Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.
MINDCURE’s Update Hints At Big Things To Come
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.
Cybin Granted DEA Schedule I Manufacturing License
Cybin announces receiving its DEA Schedule I Manufacting License, necessary to work with Schedule I controlled substances in the U.S.
